News & Blog

Press Release and Community Statement: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Webinar Recording: Biogen May 2025 Update

Webinar Recording: Lexeo Therapeutics May 2025 Update

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Gehr Family shares their FA journey, how they raise awareness of Friedreich’s ataxia, and the upcoming Cure FA Soirée with local media outlets

Community Statement: Biogen announces BRAVE Phase 3 Pediatric Study of Omaveloxolone

April/May 2025 – Advocacy Newsletter

Webinar Recording: Solid Biosciences April 2025 Update

Press Release & Community Update: Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

March 2025 – Advocacy Newsletter

Press Release & Community Update: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results